Akeso (SEHK:9926) reported long term survival data from a Phase II study of cadonilimab in advanced cervical cancer, highlighting durable benefits in a setting with limited treatment options. The ...
Before we start, I want to remind everyone that remarks made during this conference call, as well as supplemental information ...
There’s just something delightful about scaled items. Big things shrunk down, like LEGO’s teeny tiny terminal brick? Delightful. Taking that terminal brick and scaling it back to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results